Pharmaceutical Sciences ETDs
Publication Date
Spring 1-10-2017
Abstract
There have been many changes in nuclear medicine and molecular imaging field as several radiopharmaceuticals have recently been approved and many others on the horizon. Ensuring the compliance with the increasingly aggressive national, federal, and state regulatory has become a critical piece of PET manufacturing and Nuclear Pharmacy.
As a nuclear pharmacist, I have been searching for the way I can better contribute to the progress of this field with an ultimate goal of proving safe and effective healthcare to the patients. In order to do so, strengthening my expertise is essential. In this thesis, I would like to capture and narrate my professional growth, by focusing on three projects, 1) Assisting in translational work for a radiolabeled monoclonal antibody, 2) Performing Germanium analysis, and 3) Establishing an environmental monitoring program at my work place.
First Committee Member (Chair)
Jeffrey P. Norenberg, PharmD, PhD,
Degree Name
Pharmaceutical Sciences
Second Committee Member
Kristina M. Wittstrom, PhD
Level of Degree
Masters
Third Committee Member
Stephen M. Moerlein, PhD
Department Name
College of Pharmacy
Language
English
Document Type
Thesis
Keywords
PET Nuclear Pharmacist, Clinical Translation, radiolabeled monoclonal antibody, Germanium analysis, environmental monitoring program
Recommended Citation
Oyama, Reiko. "Role of Nuclear Pharmacist in Clinical Translation of Positron Emission Tomography (PET) Radiopharmaceuticals and Environmental Monitoring of Facility." (2017). https://digitalrepository.unm.edu/phrm_etds/15